GET DAILY SIGNALSLigand Pharmaceuticals (LGND) Shows Resilience in Q3 with Royalty Growth and Raised EPS Outlook
Key Takeaways
- Adjusted diluted earnings per share (EPS) of $2.67 beat the consensus estimate of roughly $2.30, while total revenue of $78.75 million also came in above expectations.
- Royalty revenue climbed 51% year over year to $70.3 million, driven by the completed XOMA Royalty acquisition and continued momentum from key assets such as Filspari.
- The company posted a generally accepted accounting principles (GAAP) net loss of $1.43 per share, reflecting one-time XOMA transaction costs and non-cash mark-to-market adjustments on equity investments.
- Management raised full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75, up from $9.00 to $9.50, while reaffirming its revenue outlook.
- Filspari became Ligand's largest royalty asset at an estimated $16.8 million for the quarter, up 85% year over year.
- Ligand ended the quarter with roughly $750 million in deployable capital to pursue additional royalty acquisitions and strategic investments.
Why This Quarter Matters
Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, earning income by acquiring royalty rights to medicines developed by other companies rather than commercializing drugs itself. This quarter carries added significance because it is the first full reporting period to reflect the July 14, 2026 acquisition of XOMA Royalty, a transformative $739 million deal that more than doubled the company's portfolio to over 200 royalty assets. I’m watching this closely to see whether the enlarged royalty base can sustain growth, whether integration costs are manageable, and how management's capital deployment strategy translates into adjusted earnings. The report also offers an early read on Filspari's commercial trajectory following its April 2026 approval for a second rare kidney disease. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Ligand reported total revenue and income of $78.7 million for the third quarter of 2026, down from $115.5 million in the prior-year period, which included $53.1 million of one-time income tied to the sale of the Pelthos business. Excluding that divestiture-related income, core revenue grew 26% year over year. Royalty revenue, the company's central growth driver, rose 51% to $70.3 million, including $12.3 million from XOMA-acquired assets recognized in the roughly 11 weeks following the deal's close.
On a GAAP basis, LGND posted a net loss of $28.5 million, or $1.43 per share, compared with net income of $117.3 million, or $5.68 per share, a year earlier. The swing primarily reflected $35 million of one-time XOMA transaction and integration costs and a $35.7 million non-cash mark-to-market loss on equity investments. Adjusted diluted EPS, which excludes such items, was $2.67, above the consensus estimate of approximately $2.30 but below the prior-year figure of $3.09, which benefited from one-time Zelsuvmi out-license income. General and administrative (G&A) expenses rose to $72.6 million from $28.4 million, largely due to acquisition-related costs and an expanded business development team.
Market Reaction and Investor Sentiment
Investor sentiment into the report was mixed, as the headline year-over-year comparisons were distorted by last year's divestiture income. The clean adjusted EPS beat and the second guidance raise of the year reinforced confidence in the underlying royalty model, even though revenue guidance was only reaffirmed rather than increased. The market's interpretation focused on the quality of the royalty growth: legacy royalties grew 25% to $58.1 million, meaning the quarter did not depend solely on newly acquired assets. However, analysts noted that GAAP results remain noisy due to mark-to-market swings, and management acknowledged that some royalty figures, including Filspari, are based on consensus estimates because partner companies report on different schedules, leaving room for later true-ups.
Forward Outlook and Key Factors to Monitor
Ligand expects fourth-quarter revenue to strengthen, driven by a full quarter of XOMA royalties compared with the partial contribution in the third quarter. Many of the company's royalty agreements also include tiered rates that step up as product sales grow, with higher tiers typically reached later in the year.
For the full year, management reaffirmed royalty revenue guidance of $225 million to $250 million and total revenue of $270 million to $310 million, while raising adjusted diluted EPS guidance to $9.50 to $9.75. Investors will be watching whether the company delivers toward the upper end of the royalty range, given the wide implied fourth-quarter spread.
Beyond the current fiscal year, several catalysts could shape the story. Palvella's Qtorin rapamycin application received priority review with a U.S. Food and Drug Administration (FDA) decision date in February 2027, and management has pointed to up to seven pivotal clinical readouts through 2027. Capital deployment also remains active, including a $23 million royalty interest in Ryjunea and an up to $47 million financing with AvenCell Therapeutics. As always with royalty aggregators, the timing of partner product sales, milestones, and clinical outcomes remains a key variable in reported results. From what I see, this is important because the pace of new deals and product launches will determine how quickly the portfolio expands.
Using AI Tools for Deeper Analysis
One tool I find particularly useful for this kind of analysis is Tickeron’s AI Screener. It allows me to quickly filter through biotech names and identify comparable royalty plays based on fundamentals and technical signals. The platform helps surface ideas across the broader market and supports a more structured approach to evaluating opportunities like those in Ligand’s space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for LGND shows an upward move is likely
LGND's Aroon Indicator triggered a bullish signal on October 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 259 similar instances where the Aroon Indicator showed a similar pattern. In 216 of the 259 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LGND as a result. In 71 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for LGND just turned positive on October 21, 2026. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for LGND crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +3.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 258 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for LGND moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 27 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
LGND broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.650) is normal, around the industry mean (3.154). P/E Ratio (31.798) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (1.267) is also within normal values, averaging (9.059). Dividend Yield (0.006) settles around the average of (131.299) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology
Advertisement